MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
MaxCyte (NASDAQ: MXCT) will release first quarter 2026 financial results after the U.S. market close on May 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MaxCyte (NASDAQ: MXCT) will release first quarter 2026 financial results after the U.S. market close on May 12, 2026. Company management will host a conference call at 4:30 p.m. Eastern Time. Investors must register online in advance. A live and archived webcast will be available on the Events section of the MaxCyte investor website at https://investors.maxcyte.com/.
Details
News Market Reaction – MXCT
On Apr 30, the first trading day after this news, MXCT closed 7.63% above the previous close.
Data tracked by StockTitan Argus for the Apr 30 session.
Key Figures
- Q1 2026 earnings date
- May 12, 2026
- Scheduled release after U.S. market close
- Earnings call time
- 4:30 p.m. Eastern Time
- Conference call to discuss Q1 2026 results
Previous Earnings date Reports
-
Set date and time for Q4 and full-year 2025 financial results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing characterization assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on LinkedIn.
Investor Relations
Gilmartin Group
David Deuchler, CFA
ir@maxcyte.com
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.